Oblimersen for the treatment of patients with chronic lymphocytic leukemia

Por Cheson, Bruce D
Publicado em 2007

Role of bendamustine in the treatment of chronic lymphocytic leukemia

Por Jamshed, Saad, Cheson, Bruce D
Publicado em 2009

State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”

Por Kostakoglu, Lale, Cheson, Bruce D.
Publicado em 2013

The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia

Por Nair, Kruti Sheth, Cheson, Bruce
Publicado no Ther Adv Hematol (2016)

Asymptomatic diffuse “encephalitic” cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia: case report and review of the literature

Por Abedalthagafi, Malak, Rushing, Elisabeth J, Garvin, David, Cheson, Bruce, Ozdemirli, Metin
Publicado em 2010

Reply to M.C. Chamberlain

Por Rubenstein, James L., Cheson, Bruce D., Jung, Sin-Ho, Kaplan, Lawrence D.
Publicado em 2014

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Por Cheson, Bruce D., Fisher, Richard I., Barrington, Sally F., Cavalli, Franco, Schwartz, Lawrence H., Zucca, Emanuele, Lister, T. Andrew
Publicado no J Clin Oncol (2014)

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 + indolent NHL: Correlation between clinical responses and AUC pharmac...

Por Casulo, Carla, Vose, Julie M., Ho, William Y., Kahl, Brad, Brunvand, Mark, Goy, Andre, Kasamon, Yvette, Cheson, Bruce, Friedberg, Jonathan W.
Publicado no Clin Immunol (2014)

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Por O'Brien, Susan M., Claxton, David F., Crump, Michael, Faderl, Stefan, Kipps, Thomas, Keating, Michael J., Viallet, Jean, Cheson, Bruce D.
Publicado no Blood (2009)

Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

Por Rubenstein, James L., Hsi, Eric D., Johnson, Jeffrey L., Jung, Sin-Ho, Nakashima, Megan O., Grant, Barbara, Cheson, Bruce D., Kaplan, Lawrence D.
Publicado em 2013

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Por Morrison, Vicki A., Jung, Sin-Ho, Johnson, Jeffrey, LaCasce, Ann, Blum, Kristie A., Bartlett, Nancy L., Pitcher, Brandelyn N., Cheson, Bruce D.
Publicado no Leuk Lymphoma (2014)

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

Por Cheson, Bruce D., Brugger, Wolfram, Damaj, Gandhi, Dreyling, Martin, Kahl, Brad, Kimby, Eva, Ogura, Michinori, Weidmann, Eckhart, Wendtner, Clemens-Martin, Zinzani, Pier Luigi
Publicado no Leuk Lymphoma (2016)

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

Por Cheson, Bruce D., Byrd, John C., Rai, Kanti R., Kay, Neil E., O'Brien, Susan M., Flinn, Ian W., Wiestner, Adrian, Kipps, Thomas J.
Publicado em 2012

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

Por Leonard, John P., Jung, Sin-Ho, Johnson, Jeffrey, Pitcher, Brandelyn N., Bartlett, Nancy L., Blum, Kristie A., Czuczman, Myron, Giguere, Jeffrey K., Cheson, Bruce D.
Publicado no J Clin Oncol (2015)

A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Por Grant, Barbara W., Jung, Sin-Ho, Johnson, Jeffrey L., Kostakoglu, Lale, His, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.
Publicado em 2013

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correl...

Por HSI, ERIC D., JUNG, SIN-HO, LAI, RAYMOND, JOHNSON, JEFFREY L., COOK, JAMES R., JONES, DAN, DEVOS, SVEN, CHESON, BRUCE D., DAMON, LLOYD E., SAID, JONATHAN
Publicado em 2008

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendam...

Por Cheson, Bruce D., Trask, Peter C., Gribben, John G., Dimier, Natalie, Kimby, Eva, Lugtenburg, Pieternella J., Thieblemont, Catherine, Wassner-Fritsch, Elisabeth, Launonen, Aino, Sehn, Laurie H.
Publicado no Ann Hematol (2016)

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer In...

Por Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillaume, Döhner, Hartmut, Hillmen, Peter, Keating, Michael J., Montserrat, Emili, Rai, Kanti R., Kipps, Thomas J.
Publicado em 2008

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Por Liu, Hongtao, Johnson, Jeffrey L., Koval, Greg, Malnassy, Greg, Sher, Dorie, Damon, Lloyd E., Hsi, Eric D., Bucci, Donna Marie, Linker, Charles A., Cheson, Bruce D., Stock, Wendy
Publicado em 2012

CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells

Por Du, Juan, Lopez-Verges, Sandra, Pitcher, Brandelyn N., Johnson, Jeffrey, Jung, Sin-Ho, Zhou, Lili, Hsu, Katharine, Czuczman, Myron S., Cheson, Bruce, Kaplan, Lawrence, Lanier, Lewis L., Venstrom, Jeffrey M.
Publicado no Cancer Immunol Res (2014)